

TABLE OF CONTENTS

<p style="text-align: center;">Volume One</p> <p style="text-align: center;">How to Use This Service</p> <p style="text-align: center;">Newsletters</p> <p style="text-align: center;">Tab 100: Overview of FDA Device Regulation</p> <p>Executive Summary ¶100</p> <p style="padding-left: 20px;">Importance of Premarket Notification —</p> <p style="padding-left: 40px;">510(k)..... ¶101</p> <p style="padding-left: 40px;">FDA’s Postmarket Information Requirements ¶102</p> <p style="padding-left: 40px;">CDRH Current “State of the Union” ¶103</p> <p style="padding-left: 40px;">CDRH Executive Organizational Chart..... ¶104</p> <p style="padding-left: 40px;">CDRH Offices’ Organizational Charts..... ¶105</p> <p>Scope of FDA Regulation of Devices ¶110</p> <p style="padding-left: 20px;">Products Subject to Regulation..... ¶111</p> <p style="padding-left: 20px;">Persons Subject to Regulation ¶112</p> <p>The Path to the Marketplace ¶120</p> <p style="padding-left: 20px;">Regulatory Classification ¶121</p> <p style="padding-left: 20px;">Product Development..... ¶122</p> <p style="padding-left: 20px;">Registration, Listing and Product Labeling ¶123</p> <p style="padding-left: 20px;">Manufacturing Controls..... ¶124</p> <p style="padding-left: 20px;">Export and Import Clearances ¶125</p> <p style="padding-left: 20px;">Role of CDRH’s Ombudsman ¶126</p> <p>Obligations After Marketing..... ¶130</p> <p style="padding-left: 20px;">Reporting of Voluntary Remedial Actions ¶131</p> <p style="padding-left: 20px;">Reporting Certification..... ¶132</p> <p style="padding-left: 20px;">Postmarket Surveillance..... ¶133</p> <p style="padding-left: 20px;">Device Tracking ¶134</p> <p>Compliance and Enforcement Remedies ¶140</p> <p style="padding-left: 20px;">Administrative Remedies..... ¶141</p> <p style="padding-left: 20px;">Judicial Remedies ¶142</p> <p>FDA and Other Federal Agencies and Laws ¶150</p> <p style="padding-left: 20px;">Electronic Product Radiation Control</p> <p style="padding-left: 40px;">Provision ¶151</p> <p style="padding-left: 40px;">Environmental Protection Agency Authorities ¶152</p> <p style="padding-left: 40px;">Centers for Medicare and Medicaid Services ¶153</p> <p style="padding-left: 40px;">Federal Trade Commission Authorities ¶154</p> <p style="padding-left: 40px;">Consumer Product Safety Commission</p> <p style="padding-left: 80px;">Authorities..... ¶155</p> <p>FDA and State Regulation and Preemption ¶160</p> <p style="text-align: center;">Tab 200: FDA Jurisdiction Over Devices</p> <p>Executive Summary ¶200</p> <p style="padding-left: 20px;">Definition and Jurisdiction of Combination</p> <p style="padding-left: 40px;">Products..... ¶201</p> <p>Definition of a Device ¶210</p> <p style="padding-left: 20px;">FDA Criteria for Device Definition ¶211</p> <p style="padding-left: 20px;">“Intended Use”..... ¶212</p> <p>Court Interpretations of the FDA’s</p> <p style="padding-left: 20px;">Jurisdiction ¶220</p> <p>FDA’s Application of the Device Definition ¶230</p> <p style="padding-left: 20px;">Components, Parts, and Accessories..... ¶231</p> <p style="padding-left: 20px;">Diagnostic and Therapeutic Devices..... ¶232</p> <p style="padding-left: 20px;">Computer Products and Mobile</p> <p style="padding-left: 40px;">Medical Applications ¶233</p> <p style="padding-left: 40px;">Human Tissue Products..... ¶234</p>	<p>Combination Products..... ¶240</p> <p style="padding-left: 20px;">Historical Context ¶241</p> <p style="padding-left: 20px;">Statutory Procedures To Regulate</p> <p style="padding-left: 40px;">Combination Products..... ¶242</p> <p style="padding-left: 40px;">Regulations and Inter-Center Agreements ¶243</p> <p style="padding-left: 40px;">Request for Designation of a Combination</p> <p style="padding-left: 80px;">Product ¶244</p> <p style="padding-left: 80px;">Review Times for Combination Products ¶245</p> <p style="padding-left: 40px;">Disputing the Timeliness of Premarket</p> <p style="padding-left: 80px;">Reviews of Combination Products..... ¶246</p> <p style="padding-left: 40px;">Postmarket Regulation of Combination</p> <p style="padding-left: 80px;">Products..... ¶247</p> <p style="text-align: center;">Tab 300: Registration, Listing, and Labeling Requirements</p> <p>Executive Summary ¶300</p> <p>Statutory Framework for Registration and Listing..... ¶310</p> <p>Establishment Registration and Device Listing Regulations ¶320</p> <p style="padding-left: 20px;">Who Must Register ¶321</p> <p style="padding-left: 20px;">Devices That Must Be Listed..... ¶322</p> <p style="padding-left: 20px;">Information Required by Listing</p> <p style="padding-left: 40px;">Regulations ¶323</p> <p>Obligations of Foreign Establishments and Distributors..... ¶330</p> <p style="padding-left: 20px;">Distributor Reporting and Foreign</p> <p style="padding-left: 40px;">Establishment Requirements..... ¶331</p> <p>Exemptions for Device Establishments ¶340</p> <p>General Labeling Provisions ¶350</p> <p style="padding-left: 20px;">Representations About Intended Use..... ¶351</p> <p style="padding-left: 20px;">Advertising and Promotion ¶352</p> <p>Labeling of Over-the-Counter Devices..... ¶360</p> <p style="padding-left: 20px;">Content of OTC Device Labels..... ¶361</p> <p style="padding-left: 20px;">Adequate Directions For Use ¶362</p> <p>Exemptions From Adequate Directions For Use ¶370</p> <p style="padding-left: 20px;">Prescription Devices ¶371</p> <p style="padding-left: 20px;">Loss of Exemption from Labeling</p> <p style="padding-left: 40px;">Requirements ¶372</p> <p style="padding-left: 40px;">Other Exemptions ¶373</p> <p style="padding-left: 40px;">Labeling Exemption for Shipping Sterile</p> <p style="padding-left: 80px;">Devices..... ¶374</p> <p>Labeling of In Vitro Diagnostic Products ¶380</p> <p style="padding-left: 20px;">Content of Label ¶381</p> <p style="padding-left: 20px;">Content of Package Insert ¶382</p> <p style="padding-left: 20px;">Use of Symbols for Professional-use In Vitro</p> <p style="padding-left: 40px;">Diagnostic Products ¶383</p> <p style="padding-left: 40px;">Labeling Exemptions for In Vitro</p> <p style="padding-left: 80px;">Diagnostic Devices ¶384</p> <p style="padding-left: 80px;">Analyte Specific Reagents (ASRs) ¶385</p> <p style="text-align: center;">Tab 400: Classification and Reclassification</p> <p>Executive Summary ¶400</p> <p style="padding-left: 20px;">The Three Classes of Device ¶401</p> <p style="padding-left: 20px;">The Three Methods of Classification ¶402</p> <p style="padding-left: 20px;">Reclassification ¶403</p>
--	---

Table of Contents

Tab 400 (cont'd)

Purpose of Classification ¶410

Description of the Device Classes ¶420

 Class I Device Definition ¶421

 Class II Device Definition ¶422

 Class III Device Definition ¶423

Methods of Classification ¶430

 Classification of Pre-Amendments Devices ¶431

 Classification of Post-Amendments Devices ¶432

 Classification of Transitional Devices ¶433

Significance of Classification Status ¶440

Purpose of Reclassification ¶450

Reclassification Procedures ¶460

 Reclassification Petition Contents ¶461

 Reclassification of Pre-Amendments Devices ¶462

 Reclassification of Post-Amendments Devices ¶463

 Reclassification of Transitional Devices ¶464

Revision of Class III Pre-Amendments and Transitional Device Classifications ¶470

 Revision of Pre-Amendments Device Classifications ¶471

 Revision of Transitional Device Classifications ¶472

 Classification Revision for Certain Contact Lenses ¶473

Standards for Reclassification ¶480

 The Statute and Regulations ¶481

 Case Law for Reclassification ¶482

 FDA Approach to Reclassification ¶483

Tab 500: Investigational Device Exemption — IDE

Executive Summary ¶500

Purpose of Investigational Device Exemptions (IDEs) ¶510

Statutory Exemption ¶520

IDE Regulations ¶530

 What Is Covered by IDE Regulations? ¶531

 Institutional Review Boards (IRBs) ¶532

 How to Apply for IDEs ¶533

 Pre-IDE Meetings ¶534

 Investigations Exempt From IDE Regulation ¶535

 Waivers ¶536

 IDE Refuse-to-Accept Policy ¶537

 Treatment Use ¶538

 Individual Patient Access ¶539

Significant Risk Devices ¶540

 Significant Risk IDEs ¶541

 Content of Significant Risk IDE Applications ¶542

 FDA Action on IDE Applications ¶543

 Supplemental IDE Applications ¶544

Non-significant Risk Devices ¶550

 Non-significant Risk IDEs ¶551

 Content of IDE Study Proposal ¶552

 IRB Action on a Study Proposal ¶553

Responsibilities of Sponsors, Investigators, and IRBs ¶560

 IDE Sponsor Responsibilities ¶561

 IDE Investigator Responsibilities ¶562

 Investigator Financial Disclosure ¶563

IDE Record Keeping, Reporting, and Confidentiality ¶570

 IDE Record-keeping Requirements ¶571

 IDE Reporting Requirements ¶572

 IDE Confidentiality Regulations ¶573

Prohibition on IDE Promotion and Commercializing ¶580

Disapproval and Withdrawal of an IDE ¶590

 Clinical Hold ¶591

 Investigator Disqualification ¶592

Tab 600: Quality Systems

Executive Summary ¶600

 Significance of Design Control Requirements ¶601

 Significance of Personnel Requirements ¶602

 ISO 13485 Compatibility with the QS Regulation ¶603

Quality System Regulation Scope ¶610

 Who Must Comply with the QS Regulation ¶611

 Exclusions or Exemptions from the QS Regulation ¶612

 How to Obtain an Exemption or Variance ¶613

Quality Systems Requirements ¶620

 Management Responsibility ¶621

 Quality Audits ¶622

 Personnel Requirements ¶623

Design Controls ¶630

 Overview of Design Control Requirements ¶631

 Design and Development Planning ¶632

 Design Input and Output ¶633

 Design Review ¶634

 Design Verification and Validation ¶635

 Design Transfer ¶636

 Design Changes ¶637

 Design History File ¶638

 Design Controls and Investigational Device Exemptions ¶639

Document Controls ¶640

 Document Approval and Distribution ¶641

 Document Changes ¶642

Purchasing, Acceptance and Servicing Activities ¶650

 Purchasing Controls ¶651

 Acceptance Activities ¶652

 Servicing ¶653

Production and Process Controls ¶660

 Production and Processes ¶661

 Inspection, Measuring and Test Equipment ¶662

 Process Validation ¶663

Quality System Manufacturing Controls ¶670

 Identification and Traceability ¶671

 Nonconforming Product ¶672

 Labeling and Packaging Controls ¶673

 Handling and Storage Controls ¶674

 Distribution Controls ¶675

 Installation Controls ¶676

 Statistical Techniques ¶677

 Corrective and Preventive Action ¶678

<i>Tab 600 (cont'd)</i>	
Record Keeping	¶680
Device Master Record.....	¶681
Device History Record.....	¶682
Quality System Record	¶683
Complaint Files.....	¶684
Compliance Implications	¶690
Inspection Authority and Process.....	¶691
Administrative Actions the FDA Can Take.....	¶692
Judicial Enforcement	¶693
FDA's Use of Injunctions.....	¶694
Inspections by Accredited Persons.....	¶695
Tab 700: Premarket Approval — PMA	
Executive Summary	¶700
Confidentiality.....	¶701
Product Development Protocols	¶702
Interactive Reviews.....	¶703
Premarket Approval Applications	¶710
Medical Device User Fee and Modernization Act of 2002 (MDUFMA).....	¶711
Medical Device User Fee Amendments of 2007 (MDUFA II) and Medical Device User Fee Amendments of 2012 (MDUFA III)	¶712
Content Requirements.....	¶713
Primary Data	¶714
Other Data Requirements.....	¶715
Expedited Review	¶716
Shell/Modular Review	¶717
Summary Technical Document (STED) Format.....	¶718
Collaboration Meetings.....	¶719
PMA Application Process	¶720
Acceptance and Filing.....	¶721
Amendments	¶722
PMA Supplements	¶723
Panel Review of Applications and Supplements.....	¶724
Checklists for Acceptance and Filing Decisions for PMAs.....	¶725
FDA's Action on a PMA Application	¶730
Substantive Review.....	¶731
Day-100 Meetings.....	¶732
Scientific Basis for Approval	¶733
Use of PMA Data	¶734
Inspections	¶735
Post-approval Requirements	¶740
Appeal of a PMA Decision	¶750
Formal Evidentiary Hearing	¶751
Expert Advisory Committee Hearing.....	¶752
Dispute Resolution Panel Review.....	¶753
Confidentiality	¶760
PMA Suspension and Withdrawal	¶770
Premarket Reports for Reprocessed Single-use Devices.....	¶771
Humanitarian Devices	¶780
Criteria for Humanitarian Device Exemption.....	¶781
Tab 800: Premarket Notification — 510(k)	
Executive Summary	¶800
Predictability of FDA's 510(k) Determinations	¶801
Planned Changes to the 501(k) Program	¶802
510(k) Paradigm.....	¶803
Third-party Review and Declarations of Conformity.....	¶804
Purpose of Premarket Notification	¶810
510(k) as a Classification Procedure.....	¶811
510(k) as a Safety and Effectiveness Screen	¶812
Definition of Substantial Equivalence	¶820
Congress's Original Intent	¶821
FDA's Definition in Practice.....	¶822
"Different Questions" of Safety and Effectiveness	¶823
Who Must File a Premarket Notification	¶830
Marketers of "New" Devices	¶831
First-time Marketers of Devices	¶832
Persons Changing or Modifying Marketed Devices.....	¶833
What Constitutes a Significant Change or Modi- fication.....	¶834
Labeling Changes That Necessitate 510(k)s.....	¶835
Exemptions From Filing 510(k)s	¶840
Custom Device Exemption	¶841
Distributors and Repackagers Exemption.....	¶842
Class I and Class II Exemptions	¶843
Content of Premarket Notification Submission	¶850
Information Required by FDA Regulations	¶851
Summaries or Statements of Safety and Effectiveness	¶852
Special Content Requirements for Certain Class III Devices.....	¶853
510(k) Refuse-to-Accept Policy	¶854
The 510(k) Decision-making Process	¶860
Intended Use and Predicate Devices.....	¶861
Technology and Use of Data.....	¶862
Different Safety and Effectiveness Questions	¶863
Expedited Review of 510(k)s.....	¶864
510(k)-Rescission Authority	¶865
When Marketing May Begin	¶870
Confidentiality	¶880
Significance of Substantial Equivalence Determinations	¶890
Tab 900: Reporting and Tracking Requirements	
Executive Summary	¶900
MDR Requirements	¶901
MDR Rule Change.....	¶902
Overview of MDR Requirements	¶910
The Reporting Process	¶911
Written Procedures and Record Keeping.....	¶912
Exemptions from MDR.....	¶913
Manufacturer and Importer Reporting Requirements	¶920
FDA Criteria for Reportable Information	¶921
Death, Serious Injury and Malfunction Reports	¶922
30-day Reports	¶923
Five-day Reports	¶924
Supplemental Reports	¶925
Annual Certification.....	¶926

Table of Contents

Tab 900 (cont'd)

User Facility Reporting Requirements ¶930
 Individual Adverse Event Reports ¶931
 Annual User Reports ¶932
Distributor Reporting ¶940
Postmarket Surveillance ¶950
 Postmarket Transformation Initiative ¶951
 Devices Subject to PMS ¶952
 Confidentiality of Plans and Data ¶953
 FDA Postmarket Surveillance Initiatives ¶954
Tracking Requirements ¶960
 Scope of Tracking ¶961
 Devices Subject to Tracking ¶962
 Manufacturer Information Requirements ¶963
 Distributor Information Requirements ¶964
 Record-keeping Requirements ¶965
 Exemption from Requirements ¶966
 Confidentiality ¶967
 Patients' Rights ¶968
Removals and Corrections ¶970

Tab 1000: Exports and Imports

Executive Summary ¶1000
Exports ¶1010
 Export of Legal Devices ¶1011
 Export of Devices Not in Compliance With the Act ¶1012
 Export Certificates ¶1013
 Export Under Radiation Control for Health and Safety Act of 1968 ¶1014
 Export of Condemned Articles ¶1015
 Import for Export ¶1016
 Unfinished Devices ¶1017
 Devices for Exotic Diseases ¶1018
Imports ¶1020
 Obligations of Foreign Manufacturers and Importers ¶1021
 Import Procedures ¶1022
 FDA Inspection and Sampling ¶1023
 Import Detention ¶1024
 Reconditioning ¶1025
 Bond Actions ¶1026
 Import Alerts and Automatic Detentions ¶1027
 Are FDA Automatic Detentions Actually Rule-makings? ¶1028

Tab 1100: Enforcement

Executive Summary ¶1100
 Administrative Actions ¶1101
 Judicial Actions ¶1102
 The Presumption of Interstate Commerce ¶1103
Device Violations ¶1110
 Adulteration ¶1111
 Misbranding ¶1112
 Specific Prohibitions ¶1113
Administrative Recall and Notification ¶1120
 Mandatory Notifications ¶1121
 Safety Alerts ¶1122
 Mandatory Recalls ¶1123

Voluntary Recalls ¶1124
 Voluntary Recall Procedures ¶1125
Administrative Civil Penalties ¶1130
Administrative Detention ¶1140
Seizures ¶1150
Injunctions ¶1160
Criminal Prosecution ¶1170
 Misdemeanors ¶1171
 Felonies ¶1172
 Prosecutions From Criminal Prosecution ¶1173

Tab 1200: FDA Device Regulation's Relationship with Other Federal Authorities

Executive Summary ¶1200
Electronic Product Radiation Control ¶1210
 Summary ¶1211
 Radiation Control Provision of the FD&C Act and Its Purposes ¶1212
 Performance Standards ¶1213
 Certification and Initial Reporting Requirements ¶1214
 Inspection, Record-keeping, and Reporting Requirements ¶1215
 Detection and Notification for Non-complying or Defective Products ¶1216
 Corrective Action for Defective Products ¶1217
 Imported Electronic Products ¶1218
 Prohibited Acts and Enforcement ¶1219
Environmental Protection Agency Authorities ¶1220
The Centers for Medicare and Medicaid Services ¶1230
 Coverage and Reimbursement ¶1231
 CMS and FDA Regulation of Devices ¶1232
 Clinical Laboratory Improvement Amendments of 1988 ¶1233
 CLIA and FDA Regulation of Devices ¶1234
Federal Trade Commission Act ¶1240
 Organization of FTC ¶1241
 FTC and FDA Regulation of Devices ¶1242
Consumer Product Safety Act ¶1250

Tab 1300: State Regulation and Preemption

Executive Summary ¶1300
 Preemption for Product Liability ¶1301
Scope and Implementation of Preemption ¶1310
 State or Local Regulations Not Subject to Preemption ¶1311
Exemption from Preemption ¶1320
 Responsibility for Preemption Exemption ¶1321
 Procedures for Exemption — Content and Form of Application ¶1322
 Application Process for Exemption ¶1323
 Revocation of an Exemption ¶1324
 Advisory Opinions ¶1325
Personal Injury Claims ¶1330
 Strict Liability — Failure to Warn ¶1331

Tab 1300 (cont'd)

Strict Liability — Design Defects.....¶1332
Negligence¶1333
Status of Personal Injury Claim —
Relationship to Preemption.....¶1334

Appendix I: Federal Laws

**Federal Food, Drug, and Cosmetic Act, as Amend-
ed (21 USC §321 et seq.)**

Selected Sections

Chapter II — Definitions
Chapter III — Prohibited Acts
Chapter V — Drugs and Devices
Chapter VII — General Authority
Chapter VIII — Imports and Exports
Chapter IX — Miscellaneous

Volume Two

(See Volume 2 Table of Contents for more information)

Appendix II: Federal Regulations

**Appendix III: FDA Preamble, Guidance and
Other Advisory Documents**

Appendix IV: FDA Forms

Appendix V: Proposed Regulations

Glossary

Index

[The next page is Current Contents, Page 21.]